Objective/Purpose: Deformable image registration (DIR) plays an important role in dose 10 accumulation, such as incorporating breathing motion into the accumulation of the delivered dose based on daily 4DCBCT images. However, it is not yet well understood how the uncertainties associated with DIR methods affect the dose calculations and resulting clinical metrics. The purpose of this study is to evaluate the impact of DIR uncertainty on the clinical metrics derived from its use in dose accumulation. 15
Introduction

40
Stereotactic Body Radiation Therapy (SBRT) is an effective treatment option in various anatomical sites. However, due to the high dose per fraction in SBRT, even small geometric uncertainties in defining and targeting the anatomy on the planning and treatment delivery images, could potentially reduce the therapeutic ratio and increase the risk of normal tissue toxicity (1) . Geometric uncertainties, patient setup, breathing 45 motions, tumor response, and radiation-induced edema may lead to changes which compromise the delivery of the planned dose (2, 3). Therefore, it is important to understand and quantify the uncertainties in the delivered dose in SBRT patients by accurate accumulation of dose over the course of treatment (1, 4) .
50
Cone-Beam Computed Tomography (CBCT), as one of the available medical imaging technologies, has been extensively used in Image-Guided Radiotherapy (IGRT) (5) .
CBCT has shown daily changes in the anatomy that rigid alignment cannot correct.
Deformable Image Registration (DIR) determines the voxel to voxel correspondence between different images, enabling the propagation of planning contours and the 55 accumulation of the delivered dose. Dose accumulation, summing the dose delivered to the same voxel of tissue tracked over the course of treatment through DIR, can help us understand how these uncorrected errors affect the deviation of the delivered dose compared to the planned dose distribution.
Although several studies have reported on retrospective dose accumulation in the lung (6) (7) (8) , it has not translated into prospective clinical trials and widespread use. This is due in part to limitations in the implementation of the process into clinical workflow, but also due to the lack of a clear understanding of how the uncertainties associated with DIR algorithms impact the applications of the DIR especially in SBRT (9) . Previous studies 65
showed that intensity-based DIR algorithms can be erroneous in homogeneous regions of images (10) . However, through the use of inverse consistency, intensity-based DIRs can improve dose accumulation results (11, 12) . These studies highlight the need to relate clinical decision parameters (e.g. minimum dose to the target and maximum dose to the normal tissue) to the uncertainty in DIR algorithms on dose accumulation results. 70
The purpose of this work is to quantify the impact of DIR uncertainty on the clinical parameters calculated from DIR-based dose accumulation. To illustrate the concept, Morfeus, a biomechanical model based DIR, and a newly developed Hybrid version, which combines a limited scope intensity-based DIR in series with Morfeus leading to a 75 reduction in the uncertainty of 1.6 mm on average (13), will be used to perform dose accumulation in lung SBRT patients. The results of this work shows its potential to be used for further quantification of the relationship between geometric and dosimetric uncertainties in DIR-based dose accumulation.
80
Methods and Materials
Ten Non-Small Cell Lung Cancer (NSCLC) patients previously treated with SBRT over 3 or 4 fractions were used for this retrospective analysis. Each patient was previously planned for SBRT with the gross tumor volume (GTV) and dose calculations performed 85 on the end exhale phase of 4DCT using an internal target volume (ITV) constructed from the breathing motion observed on the 4DCT and a planning target volume (PTV) margin of 5 mm. All the patients were treated with 6MV energy using 3D conformal delivery technique and IGRT by 4DCBCT. 4DCBCT scans with 10 breathing phases were acquired for each fraction just prior to the delivery of the treatment. For all patients with 90 (*) sign in their number of beams in Table 1 , a subset of beams were non-coplanar. The prescribed dose ranged from 48 to 60 Gy, as shown in Table 1 . V20 was defined as the percent of the lungs' volumes excluding the GTV that received greater than 20 Gy. Two patients (9 and 10) had each two gross tumor volumes (GTVs) treated with two separate plans. Dose Heterogeneity Index (DHI) proposed by Ding et al. (14) was used to 95 determine the level of inhomogeneity of the plan within the PTV. The 4DCT and 4DCBCT had the same voxel size of 0.9 x 0.9 x 2.5 mm 3 . In some cases for 4DCBCT, the resolution was a slightly higher with 0.8 x 0.8 x 2.0 mm 3 . The inhale and exhale dose grids which were imported from the treatment planning system (TPS) (Pinnacle v9.2, Philips Medical Systems, Madison, WI), had a voxel size of 2.5 x 2.5 x 2.5 mm 3 , which 100 was larger than those of the 4DCT and 4DCBCT images. 
Modeling and Deformable Image Registration
For each patient, 3D tetrahedral models of the lungs, body, and the GTV(s) were created from contours on the end-inspiration 4DCT in the TPS, as previously described (13) .
Additional normal tissues, including esophagus, trachea, central bronchus, and heart were 110 also modeled by assigning appropriate material properties to subsets of body tetrahedrons (using their imported contours from TPS to classify the tetrahedrons to the tissue).
To model the breathing motion defined by the 4DCT, the inhale 4DCT image was 115 deformed to the exhale 4DCT (predicted dose, Figure 1) . To model the inter-fraction motion of patient over the course of treatment and the intra-fraction breathing motion at the time of treatment, the inhale 4DCT image was deformed to the inhale 4DCBCT at the treatment fraction and then to the exhale 4DCBCT image (accumulated dose, Figure 1 were assigned to each organ creating a heterogeneous multi-organ model (15) . The deformations were then determined by solving for displacements of internal nodes using commercial physics solver software (ABAQUS, ABAQUS Inc, Pawtucket, RI).
The second DIR algorithm, the Hybrid method, was performed by refining the 130 deformations obtained by Morfeus through a B-spline based intensity-based registration (Drop, Munich, Germany) (16) . In the hybrid process, it was ensured that the refinement step produces small magnitude differences with a guaranteed positive Jacobian resulting in an overall biomechanically plausible estimation of the ground truth deformations. The Hybrid method reduces the local residual uncertainties in Morfeus results as 135 demonstrated in (13) and confirmed in DIR validation section.
Model Validation
Target registration error (TRE) was used to evaluate the uncertainty of the deformable registration. TRE was calculated based on the Euclidean distance of corresponding 140 anatomical points selected on the inhale and exhale planning CT images. A minimum of 29 (average of 33) points per lung per patient were selected by an expert. Effort was made to select the points with the highest possible spatial dispersion throughout the lung regions. The intra-observer variability was calculated by having the same expert (MV) reselect the points on the exhale CT when shown the points on the inhale CT. The GTV 145 contour manually drawn on the inhale CT was mapped onto the exhale CT using both Morfeus and Hybrid. The Dice Similarity Coefficient (DSC) was computed between the mapped GTV and the manually drawn GTV on the exhale CT. In addition to DSC, the difference in the Centre of Gravity (COG) of the tumor on the inhale and exhale CT was measured and compared to the COG shift calculated from Morfeus and Hybrid. 150
Quantification of the DIR uncertainty (using both Morfeus and Hybrid) was also performed using the DSC and the surface distance (based on Hausdorff distance) values obtained for each registration step in each fraction. The GTVs were contoured on each pair (inhale and exhale) of the 4DCBCT images from each fraction. The GTV contours 155 mapped from the inhale CT onto each 4DCBCT using the DIR and the manually drawn GTV contours on the each 4DCBCT image were used to calculate the DSC and the surface distance values for each patient's tumor over the entire treatment course. Figure 1 illustrates the three different dose terminologies in this paper, static, predicted, and accumulated dose, using a schematic of how they are calculated. The experiments were designed to build on each previous step, as outlined in Figure 1 .
Static, Predicted and Accumulated dose 160
Static dose refers to the clinical plan on the exhale phase of the 4DCT, which accounts 165 for the breathing motion through the use of an asymmetric PTV margin, but does not account for the normal tissue motion in and out of the PTV during breathing motion. In the static dose case, the uncertainty in DIR impacts the mapping of the GTV contour from the inhale CT to the exhale CT and the quantification of the dose delivered to the warped GTV when the GTV is in the exhale breathing position only (i.e. there is no dose 170 accumulation in this initial step). As shown in Figure 1 accumulation is performed based on DIR results and a previously published periodic asymmetric probability density function method to model the breathing motion between inhale and exhale states (17) . For each tetrahedral element, dose is determined based on the relative time weights reflecting the asymmetry of the breathing cycle (18) . This dose represents an estimate of the dose that would be delivered assuming perfect daily image 185 guidance and consistent breathing motion from 4DCT at each fraction. The dose for each tetrahedral element is the summed in 6 breathing increments from the inhale to the exhale state. In the predicted dose case, the uncertainty in the DIR impacts the mapping of the GTV contour onto the inhale image as well as the accumulated dose, which is determined from tracking the tissue between CT images based on the DIR. Since the dose is 190 calculated over a breathing cycle rather than just one extreme phase (as it is computed in the static dose), the impact of DIR-based uncertainties on the clinical metrics is expected to be less in the predicted dose case than in the static dose case. Because, the largest dose changes occur at the extreme exhale phase where DIR uncertainties are largest. However, in the predicted dose, whereby the dose is summed in six weighted increments including 195 the exhale step, the exhale dose has limited contribution in the overall dose.
The accumulated dose (Figure 1 
Dose accumulation parameters
A standard method of reporting the dose to the tumor is the use of the minimum dose to a 215 small (less than 0.5 cc) volume of the tumor (19). Therefore, the sensitivity of this parameter, minimum dose to 0.5 cc of the tumor (denoted as Dmin), was used to quantify the impact of the uncertainty in DIR-based dose accumulation. Dmin was calculated for the static dose, predicted dose, and accumulated dose using Morfeus and Hybrid to determine the sensitivity of the Dmin parameter on the DIR uncertainty. 220
Wilcoxon signed rank test was used to determine whether the difference in Dmin results obtained using each of the DIR algorithms was statistically significant. Wilcoxon signed rank test is especially useful for Dmin in this study since the normal distribution assumption regarding the Dmin data could not be made. A similar test was performed for 225 the TRE validation, COG mapping, and DSC values to determine the statistical significance. Linear regression model was used to test the statistical relationship between planning and geometric error parameters and various Dmin. Adjusted R 2 value was obtained for the overall regression, and p-values were reported to indicate whether each parameter was statistically significant in predicting Dmin. 230
Results
Validation of DIR (inhale 4DCT-exhale 4DCT)
Table 2 summarizes the uncertainty of the two DIR methods using the overall TRE as 235 well as DSC for the tumor contour propagation. The average TRE for the Hybrid method is 1.2±1.0 mm compared to 2.8±1.6 mm using Morfeus (p = 0.002). The intra-observer variability was within the voxel size of the images (13) . The DSC was on average increased by 0.13 using Hybrid compared to Morfeus (p = 0.002), however the range of improvement was up to 0.33. The Euclidean distance between the inhale and exhale 240 tumor (GTV) COG is also shown in Table 2 . On average, the COG motion of the GTV between inhale and exhale was 4.9 mm. The average residual error in predicting the COG of the GTV on the exhale image, when using DIR to map the contour, was 2.9 mm using Morfeus and reduced to 0.9 mm using the Hybrid registrations (p < 0.0005). 
Static Dose -Impact of DIR-based contour mapping on single state dose assessment
In the first experiment, the DIR algorithms were used to map the GTV contour from the inhale CT to the exhale CT where the planning dose grid is available from the TPS, as well as the actual GTV contour. To understand how uncertainties in DIR algorithms lead to differences in Dmin, the geometric deviation from the original exhale GTV contour 255 (the planning GTV) measured by the DSC, a surface distance (based on Hausdorff distance), DIR-mapped exhale tumor volume differences, and DHI of the plan were reported in Table 3 . The Dmin difference between the two DIR algorithm was significantly different (p = 0.05). The largest Dmin differences were present in patients 3 and 6 with over 3 Gy differences. Both patients had high DHI indicating high dose 260 heterogeneity within the PTV which increases the chance of sensitivity of Dmin to geometric errors measured by DSC and volume differences. Patient 3 had a substantial (8.4 cc) change in the GTV volume manually contoured on the inhale and exhale 4DCT.
Linear regression analysis showed that DHI, volume, DSC, and surface distance differences could predict Dmin differences with adjusted R 2 = 0.81 and p-values of 0.424, 265 0.003, 0.007, and 0.806 for each parameter, respectively. The analysis indicates that the selected parameters were able to describe 81% of the variations in Dmin differences.
Although, in this experiment DHI and surface distance differences did not statistically significantly contribute in predicting Dmin differences possibly due to small number of patients. Nevertheless, summarizing the relationship between these parameters and Dmin 270 in practical ranges shows promise in identifying the potentially significant Dmin differences. As shown in Table 3 , over 50% (n = 10) of the patients with more than 1 Gy difference exhibited at least three of the following three characteristics: DHI>15, volume differences>5%, DSC differences>0.08, and surface distance differences>1.5 mm. 
Predicted Dose -Impact of DIR-based dose accumulation over a breathing cycle 280
The differences between the predicted dose (the DIR-based accumulated dose using the breathing motion modeled from 4DCT) using the DIR algorithms are presented in the far right column of Table 3 . The Dmin differences between the DIR algorithms were approaching significant (p = 0.08) with larger than 1 Gy in Patient 3 only. Linear regression model revealed that DHI, volume, DSC, and surface distance differences were 285 55% (R 2 = 0.55) predictor of variations in Dmin difference with p-values of 0.009, 0.885, 0.229, and 0.805, respectively. Despite the subtlety of the predicted dose differences, the results of Table 3 show that when all of the three criteria related to the plan and DIR uncertainty (DHI>15, volume differences>5%, DSC differences>0.08, and surface distance differences>1.5 mm) are met, it is still expected to encounter over 1 Gy in the 290 predicted Dmin difference. Previously, Rosu et al (22) investigated the magnitude of changes over a breathing cycle. They found that the largest differences in the dose due to breathing motion from inhale to exhale did not exceed 2% in the point dose, and were limited to <0.5% using various clinical metrics. In the current study, the breathing motion was linearly modeled using two extreme phases of inhale and exhale with the help of 295 DIR. The dose was accumulated in six weighted increments, which led to less pronounced effect of the extreme phases, and thus, Dmin differences were subtle compared to the static dose where only the variations on exhale dose were examined.
Accumulated Dose -Impact of DIR-based dose accumulation over treatment fractions 300
In the last experiment, the total accumulated dose (the DIR-based accumulated dose that accounts for residual uncertainties at treatment delivery and the breathing motion modeled from 4DCBCT just prior to treatment delivery) was calculated using both DIR methods. The differences in Dmin in the GTV as well as DSC, surface distance, and DIRmapped GTV volume difference statistics were obtained for each tumor in each patient. 305
Adjusted R 2 value of 0.53 with p-values of 0.175, 0.988, 0.122, and 0.028 were obtained using a linear regression model for DHI, volume, DSC, and surface distance differences in predicting Dmin differences. Table 4 shows that patients 2, 3, and 7 had greater than 2
Gy differences in Dmin. For patients 3 and 7, DSC and surface distance differences, DHI and tumor volumes were over 0.08, 1.5 mm, 20, and 27 cc, respectively. Dmin 310 differences between the two DIR algorithms were not statistically significant (p = 0.27).
Dosimetric uncertainties due to geometric differences in DIR algorithms can be more amplified when the tumor volume is large and DHI is high (more heterogeneity in the plan). For Patient 2, although the tumor volume and DHI were lower compared to previous patients, the dosimetric difference was substantial due to high DSC difference. 315
For the remaining patients, one (or more) of the four parameters (DSC, surface distance, volume, DHI) was too small to produce any substantial difference in Dmin in the tumor.
The result of Table 4 indicates that for tumor volumes>25 cc, when the DHI>20 reductions of DIR uncertainty (i.e. DSC differences >0.08 and surface distance difference>1.5 mm) may result in Dmin difference of more than 1 Gy in the accumulated 320 dose assessment. 
Discussion
330
This study investigated the impact of uncertainties in DIRs on a clinical decision-making dosimetric parameter in lung SBRT. Such information is important as in the field of radiation oncology the utilization of DIR increases. 4D planning has been shown to provide better prediction of dose distribution than the conventional 3D planning (9).
However, it is important to understand how the DIR uncertainty impacts the dose 335 accumulation so that the uncertainty associated with the DIR-based dose accumulation metrics can be understood.
The relationship between the uncertainties in the dose parameter (Dmin) and the combinational effect of other factors including DSC, DHI, and GTV volume aid in the 340 generation of guidelines for which the uncertainties of DIR may lead to clinically relevant dosimetric uncertainties. This is consistent with what Hardcastle et al. (12) concluded: the larger the spatial error in high gradient regions, the larger the dosimetric uncertainty. In addition, this study is also consistent with the study by Yu et al. (20) , which showed that increased DIR uncertainty can lead to more substantial dose 345 discrepancies. In the current study the quantitative measurement of DIR uncertainty (DSC and surface distance) when combined with other patient-specific properties such as tumor volume and planning heterogeneity (as an indicative of dose gradient) were shown to be an important indication of dosimetric uncertainty.
350
Deformable image registration plays a significant role in dose accumulation applications.
In this study, the impact of the accuracy of DIR was investigated on the static, predicted and total accumulated dose. Depending on the heterogeneity of the radiation plan in the tumor, a tumor volume change of 19% (between inhale and exhale), a 0.08 difference in DSC, and a minimum of 1.5 mm difference in surface distance (when mapping a GTV 355 contour onto an alternative static plan) could affect Dmin by over 3 Gy (patient 3). The biomechanical based DIR (Morfeus) did not apply any boundary conditions to the GTV directly, so the change in the GTV volume (due to variable representation of the tumor on inhale and exhale 4DCT) was not modeled, leading to a remarkable DSC and surface distance discrepancy for this patient. Large discrepancy in tumor volume results in a 360 greater possibility of covering different doses within a highly heterogeneous plan (manifested by DHI). When the DIR results were used through the breathing motion model to calculate the predicted dose, the dosimetric differences were reduced to 1 Gy (Table 3) and if three or more of the following criteria are met: 1) DHI of the plan is larger than 15, 2,3) DIR-based contour mapping leads to a DSC and surface distance differences in the tumor exceeding 0.08 and 1.5 mm, respectively, or 4) tumor volume difference is larger than 5%. The linear regression analysis showed the importance of each or a combination of these parameters in a specific dose scenario. By increasing the number of patients, it 380 would be expected to observe better correlation between the uncertainty of Dmin and possibly all four criteria listed above. In the current preliminary study, it was found that in presence of these criteria, the likelihood of a greater than 1 Gy uncertainty in Dmin is 50% when assessing the static dose on a single breathing phase, 10% for the predicted dose, and 30% for the accumulated dose for an SBRT treatment. 385
Despite the lack of a ground truth accuracy measure for DIR application in clinical images, geometric and dosimetric investigations as performed in the current study can help us move towards more reliable estimates of the true accuracy. Landmark-and surface-based techniques to assess accuracy, as were used in this study, are only one 390 component of the process to fully understand the accuracy, reliability, and behavior that is necessary prior to the clinical use of any DIR algorithm. The development and implications of additional voxel-wise methods of validating DIR algorithms, such as Jacobians, Unbalanced Energy (UE), and Inverse Consistency (IC) are under investigation for clinical usage (21) . Furthermore, correlating the dosimetric impact of 395 DIR uncertainties will inform clinicians of the clinical importance of the use of DIR (i.e., Dmin or similar planning parameters) compared to geometric measures, such as TRE.
